Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375634 · ClinicalTrials.gov registry record · Phase 4
Nasogastric Tube Insertion Using Midazolam in the Emergency Department
A Phase 4 study, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
NCT01375634: Completed Phase 4 study, sponsored by University of Vermont.
NCT01375634 is a Phase 4 study that has completed, run by University of Vermont. The registered enrollment target is 49 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01375634, a Phase 4 study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
Study Summary
Nasogastric tube placement involves insertion of a flexible tube through the nose into the stomach. Placement of the tube can irritate the nose and palate and trigger gagging, causing discomfort, even if topical or local anesthetics are used. This study aims to determine if administration of an ultra-short acting sedative agent (midazolam) into a vein before the procedure, in addition to topical local anesthetic, will decrease the level of discomfort.
Primary Outcome
Degree of pain reported by subject on a visual analog scale and a five point scale
Interventions
- DRUG Midazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
What the finished NCT01375634 record still lists
NCT01375634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Midazolam is the first listed.
NCT01375634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01375634 about?
NCT01375634 is a clinical study titled "Nasogastric Tube Insertion Using Midazolam in the Emergency Department". Nasogastric tube placement involves insertion of a flexible tube through the nose into the stomach. Placement of the tube can irritate the nose and palate and trigger gagging, causing discomfort, even if topical or local anesthetics are used. This study aims to determine if administration of an ultr...
What is the current status of trial NCT01375634?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2011-05. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01375634?
The interventions under investigation include: Midazolam (DRUG).
Who is sponsoring clinical trial NCT01375634?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01375634's enrollment target sits among peer trials
49 1323rd of 2000 higher than 670 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia